Antiarrhythmic effects and mechanisms of sodium-glucose cotransporter 2 inhibitors: A mini review

被引：7
作者：
Wu, Jinchun [1 ]
Liu, Yanmin [1 ]
Wei, Xiaojuan [1 ]
Zhang, Xiaofei [1 ]
Ye, Yi [2 ]
Li, Wei [1 ]
Su, Xiaoling [1 ]
机构：
[1] Qinghai Prov Peoples Hosp, Dept Cardiol, Xining, Peoples R China
[2] Qinghai Univ, Grad Sch, Xining, Peoples R China
来源：
FRONTIERS IN CARDIOVASCULAR MEDICINE | 2022年 / 9卷
关键词：
Na+ homeostasis; Ca2+ homeostasis; Na+-H+ exchanger regulatory factor (NHERF)1; 2; Na+-Ca2+ exchanger (NCX); ventricular arrhythmia (VAs); atrial fibrillation; arrhythmia; sodium-glucose cotransporter 2 inhibitor; SUDDEN CARDIAC DEATH; SGLT2; INHIBITORS; HEART-FAILURE; VENTRICULAR-ARRHYTHMIAS; DIASTOLIC DYSFUNCTION; ATRIAL-FIBRILLATION; ARTERIAL STIFFNESS; NA+/H+ EXCHANGER; BLOOD-PRESSURE; EMPAGLIFLOZIN;
D O I：
10.3389/fcvm.2022.915455
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a new type of oral hypoglycaemic agent with good cardiovascular protective effects. There are several lines of clinical evidence suggest that SGLT2i can significantly reduce the risks of heart failure, cardiovascular death, and delay the progression of chronic kidney disease. In addition, recent basic and clinical studies have also reported that SGLT2i also has good anti-arrhythmic effects. However, the exact mechanism is poorly understood. The aim of this review is to summarize recent clinical findings, studies of laboratory animals, and related study about this aspect of the antiarrhythmic effects of SGLT2i, to further explore its underlying mechanisms, safety, and prospects for clinical applications of it.
引用
收藏
页数：10
相关论文
共 97 条
  • [1] Effect of Sodium-Glucose Cotransporter-2 Inhibitors on Endothelial Function: A Systematic Review of Preclinical Studies
    Alshnbari, Afnan S.
    Millar, Sophie A.
    O'Sullivan, Saoirse E.
    Idris, Iskandar
    [J]. DIABETES THERAPY, 2020, 11 (09) : 1947 - 1963
  • [2] Anti-arrhythmic and inotropic effects of empagliflozin following myocardial ischemia
    Azam, Mohammed Ali
    Chakraborty, Praloy
    Si, Daoyuan
    Du, BeiBei
    Masse, Stephane
    Lai, Patrick F. H.
    Ha, Andrew C. T.
    Nanthakumar, Kumaraswamy
    [J]. LIFE SCIENCES, 2021, 276
  • [3] Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits
    Baartscheer, Antonius
    Schumacher, Cees A.
    Wust, Rob C. I.
    Fiolet, Jan W. T.
    Stienen, Ger J. M.
    Coronel, Ruben
    Zuurbier, Coert J.
    [J]. DIABETOLOGIA, 2017, 60 (03) : 568 - 573
  • [4] Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
    Baker, William L.
    Smyth, Lindsay R.
    Riche, Daniel M.
    Bourret, Emily M.
    Chamberlin, Kevin W.
    White, William B.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION, 2014, 8 (04) : 262 - 275
  • [5] Empagliflozin significantly attenuates sotalol-induced QTc prolongation in rats
    Baris, Veysel Ozgur
    Dincsoy, Berk
    Gedikli, Esra
    Erdem, Aysen
    [J]. KARDIOLOGIA POLSKA, 2021, 79 (01) : 53 - 57
  • [6] Empagliflozin Protects against Diet-Induced NLRP-3 Inflammasome Activation and Lipid Accumulation
    Benetti, Elisa
    Mastrocola, Raffaella
    Vitarelli, Giovanna
    Cutrin, Juan Carlos
    Nigro, Debora
    Chiazza, Fausto
    Mayoux, Eric
    Collino, Massimo
    Fantozzi, Roberto
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2016, 359 (01) : 45 - 53
  • [7] Cardiac effects of SGLT2 inhibitors: the sodium hypothesis
    Bertero, Edoardo
    Roma, Leticia Prates
    Ameri, Pietro
    Maack, Christoph
    [J]. CARDIOVASCULAR RESEARCH, 2018, 114 (01) : 12 - 18
  • [8] Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk
    Bhatia, Kirtipal
    Jain, Vardhmaan
    Gupta, Kartik
    Bansal, Agam
    Fox, Arieh
    Qamar, Arman
    Damman, Kevin
    Vaduganathan, Muthiah
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (06) : 1002 - 1008
  • [9] Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
    Bode, David
    Semmler, Lukas
    Wakula, Paulina
    Hegemann, Niklas
    Primessnig, Uwe
    Beindorff, Nicola
    Powell, David
    Dahmen, Raphael
    Ruetten, Hartmut
    Oeing, Christian
    Alogna, Alessio
    Messroghli, Daniel
    Pieske, Burkert M.
    Heinzel, Frank R.
    Hohendanner, Felix
    [J]. CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
  • [10] SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system
    Bonora, Benedetta Maria
    Raschi, Emanuel
    Avogaro, Angelo
    Fadini, Gian Paolo
    [J]. CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)
12345678910